Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Association Between Alterations in the Serum 25-Hydroxyvitamin D Status During Follow-Up and Breast Cancer Patient Prognosis

  • Lim, Seung Taek (Department of Surgery, Division of Breast & Thyroid Surgical Oncology, St. Vincent's Hospital, The Catholic University of Korea) ;
  • Jeon, Ye Won (Department of Surgery, Division of Breast & Thyroid Surgical Oncology, St. Vincent's Hospital, The Catholic University of Korea) ;
  • Suh, Young Jin (Department of Surgery, Division of Breast & Thyroid Surgical Oncology, St. Vincent's Hospital, The Catholic University of Korea)
  • Published : 2015.04.03
Download PDF
⟨ Previous Next ⟩

Abstract

Background: Serum vitamin D status can affect the prognosis of breast cancer patients. Our aim was to determine the association between alterations in the 25-hydroxyvitamin D [25(OH)D] status during follow-up and the prognosis of breast cancer patients. Additionally, we evaluated the association between the 25(OH)D status at the time of diagnosis and the prognosis using a detailed age and stage categorization. Materials and Methods: Four hundred and sixty-nine Korean breast cancer patients were included. We collected patient clinicopathological data, including their serum 25(OH)D concentration at diagnosis and at the annual follow-up until 4 years after diagnosis. The patients were divided according to their 25(OH)D status at diagnosis into a deficient (<20 ng/ml) and a non-deficient (${\geq}20ng/ml$) group. At follow-up, patients were categorized into the four following groups according to 25(OH)D status alterations: persistently deficient, improved, deteriorated and persistently non-deficient. Results: At diagnosis, 118 patients were classified into the deficient group and 351 into the non-deficient group. After a median follow-up period of $85.8{\pm}31.0$ months, the patients with advanced-stage disease or an older age in the non-deficient group showed a significantly better survival compared with the deficient group. Furthermore, at the 1-year follow-up of 25(OH)D status, the persistently non-deficient group and the improved group had better survival compared with the other two groups. Conclusions: Our results suggest that maintaining an optimal 25(OH)D status at diagnosis and during the 1-year follow-up period is important for improving breast cancer patient survival.

Keywords

References

  1. Alipour S, HadjiM, Hosseini L, et al (2014) Levels of serum 25-hydroxy-vitamin D in benign and malignant breast masses. Asian Pac J Cancer Prev, 15, 129-32 https://doi.org/10.7314/APJCP.2014.15.1.129
  2. Bikle D (2009) Nonclassic actions of vitamin D. J Clin Endocrinol Metab, 94, 26-34 https://doi.org/10.1210/jc.2008-1454
  3. Bilinski K, Boyages J (2013) Association between 25-hydroxyvitamin D concentration and breast cancer risk in an Australian population: an observational case-control study. Breast Cancer Res Treat, 137, 599-607 https://doi.org/10.1007/s10549-012-2381-1
  4. Carlberg C (2003) Current understanding of the function of the nuclear vitamin D receptor in response to its natural and synthetic ligands. Recent Results Cancer Res, 164, 29-42 https://doi.org/10.1007/978-3-642-55580-0_2
  5. Crew KD, Gammon MD, Steck SE, et al (2009) Association between plasma 25-hydroxyvitamin D and breast cancer risk. Cancer Prev Res, 2, 598-604 https://doi.org/10.1158/1940-6207.CAPR-08-0138
  6. Goodwin PJ, Ennis M, Pritchard KI, Koo J, Hood N (2009) Prognostic effects of 25-hydroxyvitamin D levels in early breast cancer. J Clin Oncol, 27, 3757-63 https://doi.org/10.1200/JCO.2008.20.0725
  7. Hatse S, Lambrechts D, Verstuyf A, et al (2012) Vitamin D status at breast cancer diagnosis: correlation with tumor characteristics, disease outcome and genetic determinants of vitamin D insufficiency. Carcinogenesis, 33, 1319-26 https://doi.org/10.1093/carcin/bgs187
  8. Heaney RP, Davies KM, Chen TC, Holick MF, Barger-Lux MJ (2003) Human serum 25-hydroxycholecalciferol response to extended oral dosing with cholecalciferol. Am J Clin Nutr, 77, 204-10
  9. Holick MF (2006) Vitamin D: its role in cancer prevention and treatment. Prog Biophys Mol Biol, 92, 49-59 https://doi.org/10.1016/j.pbiomolbio.2006.02.014
  10. Holick MF (2007) Vitamin D deficiency. N Engl J Med, 357, 266-81 https://doi.org/10.1056/NEJMra070553
  11. Holick MF (2009) Vitamin D status: measurement, interpretation and clinical application. Ann Epidemiol, 19, 73-8 https://doi.org/10.1016/j.annepidem.2007.12.001
  12. Holick MF, Binkley NC, Bischoff-Ferrari HA, et al (2011) Evaluation, treatment and prevention of vitamin D deficiency: an endocrine society clinical practice guideline. J Clin Endocrinol Metab, 96, 1911-30 https://doi.org/10.1210/jc.2011-0385
  13. Institute of Medicine (2010) Dietary Reference Intakes for Calcium and Vitamin D. The National Academies Press, Washington
  14. Iqbal SJ (1994) Vitamin D metabolism and the clinical aspects of measuring metabolites. Ann Clin Bio chem, 31, 109-24 https://doi.org/10.1177/000456329403100201
  15. Jacobs ET, Alberts DS, Foote JA, et al (2008) Vitamin D insufficiency in southern Arizona. Am J Clin Nutr, 87, 608-13
  16. Kermani IA, Kojidi HT, Gharamaleki JV, et al (2011) Association of serum level of 25 hydroxy-vitamin D with prognostic factors for breast cancer. Asian Pac J Cancer Prev, 12, 1381-4
  17. Kim ML, Il Kang M, Won Oh K, et al (2010) The association of serum vitamin D level with presence of metabolic syndrome and hypertension in middle-aged Korean subjects. Clin Endocrinol, 73, 330-8 https://doi.org/10.1111/j.1365-2265.2010.03798.x
  18. Kim HJ, Lee YM, Ko BS, et al (2011) Vitamin D deficiency is correlated with poor outcomes in patients with luminal-type breast cancer. Ann Surg Oncol, 18, 1830-6 https://doi.org/10.1245/s10434-010-1465-6
  19. Kim HJ, Koh BS, Yu JH, et al (2014) Changes in serum hydroxyvitamin D levels of breast cancer patients during tamoxifen treatment or chemotherapy in premenopausal breast cancer patients. Eur J Cancer, 50, 1403-11 https://doi.org/10.1016/j.ejca.2014.02.026
  20. Lee ES, Ahn J, Patk HM (2009) Serum vitamin D status of Korean postmenopausal women during the winter months. Asia Pac J ClinNutr, 18, 29-33
  21. Manson JE, Mayne ST, Clinton SK (2011) Vitamin D and prevention of cancer-ready for prime time? N Engl J Med, 364, 1385-7 https://doi.org/10.1056/NEJMp1102022
  22. McCullough ML, Weinstein SJ, Freedman DM, et al (2010) Correlates of circulating 25-hydroxyvitamin D: cohort consortium vitamin d pooling project of rarer cancers. AM J Epidemiol, 172, 21-35 https://doi.org/10.1093/aje/kwq113
  23. Mousavi-Jarrrahi SH, Kasaeian A, Mansori K, et al (2013) Addressing the younger age at onset in breast cancer patients in Asia: an age-period-cohort analysis of fifty years of quality data from the international agency for research on cancer. ISRN Oncol, 2013, 429862
  24. Palmieri C, MacGregor T, Girgis S, Vigushin D (2006) Serum 25-hydroxyvitamin D levels in early and advanced breast cancer. J Clin Pathol, 59, 1334-6 https://doi.org/10.1136/jcp.2006.042747
  25. Peppone LJ, Huston AJ, Reid ME, et al (2011) The effect of various vitamin D supplementation regimens in breast cancer patients. Breast Cancer Res Treat, 127, 171-7 https://doi.org/10.1007/s10549-011-1415-4
  26. Shi L, Nechuta S, Gao YT, et al (2014) Correlates of 25-hydroxyvitamin D among Chinese breast cancer patients. PLoS One, 9, 86467 https://doi.org/10.1371/journal.pone.0086467
  27. Vance V, Campbell S, McCargar L, Mourtzakis M, Hanning R (2014) Dietary changes and food intake in the first year after breast cancer treatment. Appl Physiol Nutr Metab, 39, 707-14 https://doi.org/10.1139/apnm-2013-0400
  28. Villasenor A, Ballard-Barbash R, Ambs A, et al (2013) Associations of serum 25-hydroxyvitamin D with overall and breast cancer-specific mortality in a multiethnic cohort of breast cancer survivors. Cancer Causes Control, 24, 759-67 https://doi.org/10.1007/s10552-013-0158-4

Cited by

  1. The impact of vitamin D pathway genetic variation and circulating 25-hydroxyvitamin D on cancer outcome: systematic review and meta-analysis vol.116, pp.8, 2017, https://doi.org/10.1038/bjc.2017.44
  2. Anticancer potential of dietary vitamin D and ascorbic acid: A review vol.57, pp.12, 2017, https://doi.org/10.1080/10408398.2015.1064086
  3. Circulating Vitamin D and Overall Survival in Breast Cancer Patients: A Dose-Response Meta-Analysis of Cohort Studies pp.1552-695X, 2017, https://doi.org/10.1177/1534735417712007